Logo image of ABUS

ARBUTUS BIOPHARMA CORP (ABUS) Stock Fundamental Analysis

NASDAQ:ABUS - Nasdaq - CA03879J1003 - Common Stock - Currency: USD

3.58  +0.05 (+1.42%)

After market: 3.58 0 (0%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ABUS. ABUS was compared to 557 industry peers in the Biotechnology industry. The financial health of ABUS is average, but there are quite some concerns on its profitability. ABUS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

ABUS had negative earnings in the past year.
In the past year ABUS has reported a negative cash flow from operations.
ABUS had negative earnings in each of the past 5 years.
In the past 5 years ABUS always reported negative operating cash flow.
ABUS Yearly Net Income VS EBIT VS OCF VS FCFABUS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M

1.2 Ratios

The Return On Assets of ABUS (-65.44%) is worse than 62.30% of its industry peers.
ABUS has a Return On Equity (-96.73%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -65.44%
ROE -96.73%
ROIC N/A
ROA(3y)-46.36%
ROA(5y)-47.53%
ROE(3y)-63.75%
ROE(5y)-63.56%
ROIC(3y)N/A
ROIC(5y)N/A
ABUS Yearly ROA, ROE, ROICABUS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

ABUS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABUS Yearly Profit, Operating, Gross MarginsABUS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K -25K

More info and screens

6

2. Health

2.1 Basic Checks

ABUS does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for ABUS has been increased compared to 1 year ago.
ABUS has more shares outstanding than it did 5 years ago.
ABUS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ABUS Yearly Shares OutstandingABUS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
ABUS Yearly Total Debt VS Total AssetsABUS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

ABUS has an Altman-Z score of -6.51. This is a bad value and indicates that ABUS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of ABUS (-6.51) is worse than 66.25% of its industry peers.
There is no outstanding debt for ABUS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.51
ROIC/WACCN/A
WACC9.05%
ABUS Yearly LT Debt VS Equity VS FCFABUS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M

2.3 Liquidity

A Current Ratio of 6.01 indicates that ABUS has no problem at all paying its short term obligations.
ABUS has a Current ratio of 6.01. This is in the better half of the industry: ABUS outperforms 61.22% of its industry peers.
A Quick Ratio of 6.01 indicates that ABUS has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 6.01, ABUS is in the better half of the industry, outperforming 61.94% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 6.01
Quick Ratio 6.01
ABUS Yearly Current Assets VS Current LiabilitesABUS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

5

3. Growth

3.1 Past

ABUS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 9.09%, which is quite good.
The Revenue for ABUS has decreased by -50.70% in the past year. This is quite bad
ABUS shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 0.53% yearly.
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
Revenue 1Y (TTM)-50.7%
Revenue growth 3Y-17.5%
Revenue growth 5Y0.53%
Sales Q2Q%15.14%

3.2 Future

The Earnings Per Share is expected to grow by 24.05% on average over the next years. This is a very strong growth
Based on estimates for the next years, ABUS will show a very strong growth in Revenue. The Revenue will grow by 94.81% on average per year.
EPS Next Y33.84%
EPS Next 2Y19.79%
EPS Next 3Y23.03%
EPS Next 5Y24.05%
Revenue Next Year1.14%
Revenue Next 2Y-15.32%
Revenue Next 3Y12.63%
Revenue Next 5Y94.81%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABUS Yearly Revenue VS EstimatesABUS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 50M 100M 150M
ABUS Yearly EPS VS EstimatesABUS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 -1 -2 -3

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

ABUS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABUS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABUS Price Earnings VS Forward Price EarningsABUS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABUS Per share dataABUS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 0.4

4.3 Compensation for Growth

A more expensive valuation may be justified as ABUS's earnings are expected to grow with 23.03% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.79%
EPS Next 3Y23.03%

More info and screens

0

5. Dividend

5.1 Amount

ABUS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ARBUTUS BIOPHARMA CORP

NASDAQ:ABUS (6/16/2025, 4:09:09 PM)

After market: 3.58 0 (0%)

3.58

+0.05 (+1.42%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-14 2025-05-14/bmo
Earnings (Next)07-30 2025-07-30/bmo
Inst Owners59.25%
Inst Owner Change8.84%
Ins Owners0.79%
Ins Owner Change0.68%
Market Cap685.68M
Analysts82
Price Target5.36 (49.72%)
Short Float %7.69%
Short Ratio11.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-4.52%
Min EPS beat(2)-23.26%
Max EPS beat(2)14.22%
EPS beat(4)2
Avg EPS beat(4)-3.43%
Min EPS beat(4)-23.26%
Max EPS beat(4)14.22%
EPS beat(8)5
Avg EPS beat(8)0.84%
EPS beat(12)8
Avg EPS beat(12)5.15%
EPS beat(16)11
Avg EPS beat(16)7.32%
Revenue beat(2)0
Avg Revenue beat(2)-2.06%
Min Revenue beat(2)-2.81%
Max Revenue beat(2)-1.32%
Revenue beat(4)0
Avg Revenue beat(4)-9.29%
Min Revenue beat(4)-29.45%
Max Revenue beat(4)-1.32%
Revenue beat(8)0
Avg Revenue beat(8)-21.02%
Revenue beat(12)2
Avg Revenue beat(12)-7.64%
Revenue beat(16)6
Avg Revenue beat(16)9.07%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-23.7%
EPS NQ rev (3m)40.63%
EPS NY rev (1m)0%
EPS NY rev (3m)26.7%
Revenue NQ rev (1m)-8.06%
Revenue NQ rev (3m)16.41%
Revenue NY rev (1m)-9.79%
Revenue NY rev (3m)20.36%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 107.09
P/FCF N/A
P/OCF N/A
P/B 8.66
P/tB 8.66
EV/EBITDA N/A
EPS(TTM)-0.4
EYN/A
EPS(NY)-0.21
Fwd EYN/A
FCF(TTM)-0.31
FCFYN/A
OCF(TTM)-0.31
OCFYN/A
SpS0.03
BVpS0.41
TBVpS0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -65.44%
ROE -96.73%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.36%
ROA(5y)-47.53%
ROE(3y)-63.75%
ROE(5y)-63.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0.05
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 6.42%
Cap/Sales 1.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.01
Quick Ratio 6.01
Altman-Z -6.51
F-Score2
WACC9.05%
ROIC/WACCN/A
Cap/Depr(3y)40.22%
Cap/Depr(5y)35.71%
Cap/Sales(3y)3.27%
Cap/Sales(5y)4.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-30%
EPS Next Y33.84%
EPS Next 2Y19.79%
EPS Next 3Y23.03%
EPS Next 5Y24.05%
Revenue 1Y (TTM)-50.7%
Revenue growth 3Y-17.5%
Revenue growth 5Y0.53%
Sales Q2Q%15.14%
Revenue Next Year1.14%
Revenue Next 2Y-15.32%
Revenue Next 3Y12.63%
Revenue Next 5Y94.81%
EBIT growth 1Y16.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y29.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y29.22%
OCF growth 3YN/A
OCF growth 5YN/A